Top Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Your Basket's Financial Footprint
Summary and key takeaways for a basket of top biotech stocks based on provided market capitalisation data.
- Large-cap dominance tends to provide stability and lower volatility, making performance similar to broad-market exposure.
- Suitable as a core holding in a diversified portfolio; not intended as a speculative, high-risk trade.
- More likely to deliver steady, long-term value rather than rapid, short-term gains.
AMGN: $162.12B
GILD: $153.96B
BIIB: $21.44B
- Other
About This Group of Stocks
Our Expert Thinking
These biotech companies are pioneering revolutionary treatments using advanced technologies like CRISPR gene editing. With favorable regulatory environments expediting approvals and growing global demand for innovative healthcare solutions, this sector offers both meaningful impact and promising financial growth opportunities.
What You Need to Know
Biotech investments can offer substantial returns but typically involve longer development cycles. The industry is projected to grow from $1.55 trillion in 2023 to approximately $3.88 trillion by 2030, with regulatory support accelerating the approval of promising treatments.
Why These Stocks
We've selected established biotech leaders and innovative disruptors working on groundbreaking medical advancements. These companies are well-positioned to respond to increasing healthcare demands as global populations age, making them potentially valuable additions to a forward-looking investment portfolio.
Why You'll Want to Watch These Stocks
Medical Game-Changers
These companies are developing treatments that could transform healthcare as we know it. From gene editing to novel therapies, they're tackling our biggest health challenges.
Explosive Growth Potential
The biotech industry is projected to grow at nearly 14% annually through 2030. Getting in now means positioning yourself at the start of what could be a remarkable expansion.
More Than Just Profits
By investing in biotech, you're not just seeking returns but also supporting companies developing treatments that could save millions of lives and improve countless others.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Drug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Automation & Software Investment Theme Overview
Recent labor data reveals a split market, with low private-sector jobless claims contrasting with high unemployment driven by federal layoffs. This dynamic creates an investment opportunity in companies providing automation, software, and efficiency-boosting services as businesses prioritize productivity over expanding their payrolls.
Oyo's IPO Plans: Hospitality Sector Recovery Explained
Global hospitality firm Oyo's parent company has revived its IPO plans, signaling renewed confidence in the travel market. This high-profile listing could ignite investor interest across the entire hospitality and travel technology sector, creating opportunities for related service providers.